Current Report Filing (8-k)
May 09 2023 - 6:35AM
Edgar (US Regulatory)
0001739104
false
0001739104
2023-05-09
2023-05-09
0001739104
us-gaap:CommonStockMember
2023-05-09
2023-05-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): May 9, 2023
Elanco
Animal Health Incorporated
(Exact name of registrant as specified
in its charter)
Indiana | |
001-38661 | |
82-5497352 |
(State
or other jurisdiction
of incorporation) | |
(Commission
File Number) | |
(I.R.S. Employer Identification No.) |
2500 Innovation Way
Greenfield, Indiana (Address of principal executive offices)
| |
46140 (Zip
Code) |
Registrant’s telephone number, including area code: (877)
352-6261
Not Applicable
(Former Name or Address, if Changed Since Last
Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
| ¨ | Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which
registered |
Common stock, no par value |
|
ELAN |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
¨ Emerging
growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 |
Results of Operation and Financial Condition. |
Attached as Exhibit 99.1
and incorporated by reference into this Item 2.02 is a copy of the press release, dated May 9, 2023, announcing the results of operations
for the fiscal quarter ended March 31, 2022 and guidance for the full year, first half and second quarter of 2023, for Elanco Animal
Health Incorporated.
The information in this Item
2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities
of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities
Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Elanco Animal Health Incorporated |
|
|
Date: May 9, 2023 |
By: |
/s/ Todd Young |
|
|
Name: Todd Young |
|
|
Title: Executive Vice President and Chief Financial Officer |
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Apr 2023 to Apr 2024